Gender Moderates the Association of Depressive Symptoms to Sexual Risk Behavior Among HIV-Positive African-American Outpatients

Babowitch, Jacklyn D.; Vanable, Peter A.; Carey, Michael P.

doi:10.1007/s10461-017-1981-5

Cited by 3 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The total scores range from 0 to 60. Previous studies report a Cronbach's α coefficient for this scale ranging from 0.85 to 0.90 [21,22]. Cronbach's α coefficient for this scale in our sample was 0.91.…”

Section: Methodssupporting

confidence: 45%

The implementation and evaluation of HIV symptom management guidelines: A preliminary study in China

Zhu

et al. 2018

International Journal of Nursing Sciences

View full text Add to dashboard Cite

Objective The overarching objective of this study was to examine the effectiveness of HIV symptom management guidelines in China in reducing the incidence and severity of symptoms and improving patients' quality of life. Methods We conducted a controlled, pre- and post-implementation design in the HIV/AIDS inpatient unit in Shanghai. Patients recruited from November 2014 to February 2015 were in the intervention group and those from October 2013 to February 2014 were in the control group. There were 74 patients in each group. Participants in the intervention group received interventions based on the HIV symptom management guidelines. Overall symptom severity, depression, and quality of life were measured in two groups at baseline, week 4, and week 8. Results Totally 126 patients completed the research, 65 in the intervention group and 61 in the control group. The total symptom severity scores showed a statistically significant difference between groups across time ( P < 0.05). It showed that frequencies of fatigue (36.9% vs. 44.3%), fever (6.2% vs. 11.5%), loss in weight (9.2% vs. 16.4%), mouth ulcers (12.3% vs. 16.4%), headaches (9.2% vs. 19.7%) and depression ( F = 1.09, P > 0.05) in the intervention group were lower than those in the control group in week 8 without statistical significance. The multilevel growth mixture model indicated a greater increase in the total score of quality of life for the group treated according to the symptom management guidelines ( P = 0.04). Conclusion The evidence-based HIV symptom management guidelines can improve a patient's quality of life and relieve negative symptoms. The guidelines can be applied in a similar context to other HIV/AIDS units or clinics.

show abstract

Section: Methodssupporting

confidence: 45%

The implementation and evaluation of HIV symptom management guidelines: A preliminary study in China

Zhu

et al. 2018

International Journal of Nursing Sciences

View full text Add to dashboard Cite

show abstract

Exploring factors associated with condom use self-efficacy and condom use among Northern and Indigenous adolescent peer leaders in Northern Canada

Logie

Lys²,

Okumu

et al. 2018

Vulnerable Children and Youth Studies

View full text Add to dashboard Cite

The association between the use of efavirenz and the occurrence of depressive disorders among HIV-treated patients: An application of Bayesian cox regression

Lai

2021

IFS

View full text Add to dashboard Cite

OBJECTIVES: Efavirenz therapy plays an important role in controlling the progression of HIV/AIDS. However, efavirenz often causes short-term side effects for the central nervous system, and it remained controversial as to whether efavirenz leads to depression or even suicidal attempt when applied for a longer period of time. The purpose of this study is to determine the association between the use of efavirenz and depressive disorders. METHODS: This study explored the use of efavirenz on HIV-infected patients using National Health Insurance Research Database (NHIRD) in Taiwan by Bayesian survival analysis and investigated whether the use of efavirenz has the risk of depressive disorders. To reduce the dependence of statistical modeling assumptions, this study applied propensity score matching to research data. RESULTS: Based on the result of this study, it can be found that the use of efavirenz (HR = 1.009, 95% CI=–0.505 0.554), gender (HR = 0.324, 95% CI = –2.544 0.381) were not significantly associated with the occurrence of depressive disorders, whereas age of HIV diagnosis (HR = 1.021, 95% CI = 0.011 0.055) was significantly associated with the occurrence of depressive disorders. This study concludes that the use of efavirenz does not in-crease the risk of depressive disorders among HIV-treated patients. CONCLUSIONS: For the care of HIV-infected patients (especially the older ones), the psychological harm from society, such as lack of social support, social stigma or unemployment is higher than the harm of medicine.

show abstract

Gender Moderates the Association of Depressive Symptoms to Sexual Risk Behavior Among HIV-Positive African-American Outpatients

Cited by 3 publications

References 30 publications

The implementation and evaluation of HIV symptom management guidelines: A preliminary study in China

The implementation and evaluation of HIV symptom management guidelines: A preliminary study in China

Exploring factors associated with condom use self-efficacy and condom use among Northern and Indigenous adolescent peer leaders in Northern Canada

The association between the use of efavirenz and the occurrence of depressive disorders among HIV-treated patients: An application of Bayesian cox regression

Contact Info

Product

Resources

About